

**Moxifloxacin Solid Formulation**

Version 2.4      Revision Date: 13.10.2021      SDS Number: 1731672-00008      Date of last issue: 23.03.2020  
Date of first issue: 05.06.2017

---

**SECTION 1: Identification of the substance/mixture and of the company/undertaking****1.1 Product identifier**

Trade name : Moxifloxacin Solid Formulation

**1.2 Relevant identified uses of the substance or mixture and uses advised against**

Use of the Sub-stance/Mixture : Pharmaceutical

**1.3 Details of the supplier of the safety data sheet**

Company : MSD  
117 16th Road  
1685 Halfway house, Midrand, South Africa

Telephone : +27 11 655 3000

E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

**1.4 Emergency telephone number**


+1-908-423-6000

---

**SECTION 2: Hazards identification****2.1 Classification of the substance or mixture****Classification (REGULATION (EC) No 1272/2008)**

Acute toxicity, Category 4	H302: Harmful if swallowed.
Eye irritation, Category 2	H319: Causes serious eye irritation.
Reproductive toxicity, Category 2	H361d: Suspected of damaging the unborn child.
Specific target organ toxicity - repeated exposure, Category 2	H373: May cause damage to organs through prolonged or repeated exposure.

**2.2 Label elements****Labelling (REGULATION (EC) No 1272/2008)**

Hazard pictograms : 

Signal word : Warning

Hazard statements : H302 Harmful if swallowed.  
H319 Causes serious eye irritation.  
H361d Suspected of damaging the unborn child.  
H373 May cause damage to organs through prolonged or repeated exposure.

Precautionary statements : **Prevention:**

## Moxifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.4	13.10.2021	1731672-00008	Date of first issue: 05.06.2017

P201 Obtain special instructions before use.  
 P270 Do not eat, drink or smoke when using this product.  
 P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**

P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/ doctor if you feel unwell. Rinse mouth.  
 P308 + P313 IF exposed or concerned: Get medical advice/ attention.  
 P337 + P313 If eye irritation persists: Get medical advice/ attention.

Hazardous components which must be listed on the label:

Moxifloxacin HCL

**2.3 Other hazards**

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

**SECTION 3: Composition/information on ingredients****3.2 Mixtures****Components**

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Moxifloxacin HCL	186826-86-8	Acute Tox. 4; H302 Eye Irrit. 2; H319 Repr. 2; H361d STOT RE 2; H373 (Liver)	>= 40 - <= 70

For explanation of abbreviations see section 16.

**SECTION 4: First aid measures****4.1 Description of first aid measures**

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
 When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.  
 Get medical attention.

**Moxifloxacin Solid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.4	13.10.2021	1731672-00008	Date of first issue: 05.06.2017

---

- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.  
If easy to do, remove contact lens, if worn.  
Get medical attention.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.  
Never give anything by mouth to an unconscious person.

**4.2 Most important symptoms and effects, both acute and delayed**

- Risks : Harmful if swallowed.  
Causes serious eye irritation.  
Suspected of damaging the unborn child.  
May cause damage to organs through prolonged or repeated exposure.

**4.3 Indication of any immediate medical attention and special treatment needed**

- Treatment : Treat symptomatically and supportively.
- 

**SECTION 5: Firefighting measures****5.1 Extinguishing media**

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical
- Unsuitable extinguishing media : None known.

**5.2 Special hazards arising from the substance or mixture**

- Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides

**5.3 Advice for firefighters**

- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

**Moxifloxacin Solid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.4	13.10.2021	1731672-00008	Date of first issue: 05.06.2017

---

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

---

**SECTION 6: Accidental release measures****6.1 Personal precautions, protective equipment and emergency procedures**

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

**6.2 Environmental precautions**

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

**6.3 Methods and material for containment and cleaning up**

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

**6.4 Reference to other sections**

See sections: 7, 8, 11, 12 and 13.

---

**SECTION 7: Handling and storage****7.1 Precautions for safe handling**

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust, fume, gas, mist, vapours or spray.  
Do not swallow.  
Do not get in eyes.  
Avoid prolonged or repeated contact with skin.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Do not eat, drink or smoke when using this product.  
Take care to prevent spills, waste and minimize release to the environment.

## Moxifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.4	13.10.2021	1731672-00008	Date of first issue: 05.06.2017

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

### 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers : Keep in properly labelled containers. Store locked up. Store in accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:  
Strong oxidizing agents

### 7.3 Specific end use(s)

Specific use(s) : No data available

## SECTION 8: Exposure controls/personal protection

### 8.1 Control parameters

#### Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Moxifloxacin HCL	186826-86-8	TWA	1000 µg/m <sup>3</sup> (OEB 2)	Internal
Cellulose	9004-34-6	TWA OEL-RL (Respirable dust)	5 mg/m <sup>3</sup>	ZA OEL
	Further information: Recommended Limit			
		TWA OEL-RL (inhalable dust)	10 mg/m <sup>3</sup>	ZA OEL
	Further information: Recommended Limit			
		STEL OEL-RL (Dust)	20 mg/m <sup>3</sup>	ZA OEL
	Further information: Recommended Limit			

### 8.2 Exposure controls

#### Engineering measures

Use feasible engineering controls to minimize exposure to compound. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

#### Personal protective equipment

Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

**Moxifloxacin Solid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.4	13.10.2021	1731672-00008	Date of first issue: 05.06.2017

---

Hand protection	aerosols.
Material	: Chemical-resistant gloves
Skin and body protection	: Work uniform or laboratory coat.
Respiratory protection	: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	: Particulates type (P)

---

**SECTION 9: Physical and chemical properties****9.1 Information on basic physical and chemical properties**

Appearance	: solid
Colour	: pink
Odour	: odourless
Odour Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: Not applicable
Evaporation rate	: No data available
Flammability (solid, gas)	: Not classified as a flammability hazard
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapour pressure	: No data available
Relative vapour density	: No data available
Relative density	: No data available
Density	: No data available
Solubility(ies)	
Water solubility	: No data available
Partition coefficient: n-octanol/water	: No data available
Auto-ignition temperature	: No data available
Decomposition temperature	: No data available
Viscosity	
Viscosity, kinematic	: No data available

**Moxifloxacin Solid Formulation**

Version 2.4      Revision Date: 13.10.2021      SDS Number: 1731672-00008      Date of last issue: 23.03.2020  
Date of first issue: 05.06.2017

---

Explosive properties : Not explosive  
Oxidizing properties : The substance or mixture is not classified as oxidizing.

**9.2 Other information**

Flammability (liquids) : No data available  
Molecular weight : Not applicable  
Particle size : No data available

---

**SECTION 10: Stability and reactivity****10.1 Reactivity**

Not classified as a reactivity hazard.

**10.2 Chemical stability**

Stable under normal conditions.

**10.3 Possibility of hazardous reactions**

Hazardous reactions : Can react with strong oxidizing agents.

**10.4 Conditions to avoid**

Conditions to avoid : None known.

**10.5 Incompatible materials**

Materials to avoid : Oxidizing agents

**10.6 Hazardous decomposition products**

No hazardous decomposition products are known.

---

**SECTION 11: Toxicological information****11.1 Information on toxicological effects**

Information on likely routes of exposure : Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

Harmful if swallowed.

**Product:**

Acute oral toxicity : Acute toxicity estimate: 1.886 mg/kg  
Method: Calculation method

**Components:****Moxifloxacin HCL:**

Acute oral toxicity : LD50 (Rat): 1.320 mg/kg

---

**Moxifloxacin Solid Formulation**

Version 2.4      Revision Date: 13.10.2021      SDS Number: 1731672-00008      Date of last issue: 23.03.2020  
Date of first issue: 05.06.2017

---

LD50 (Mouse): > 435 mg/kg

LD50 (Monkey): 1.500 mg/kg

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Moxifloxacin HCL:**

Species : Rabbit  
Result : No skin irritation

**Serious eye damage/eye irritation**

Causes serious eye irritation.

**Components:****Moxifloxacin HCL:**

Species : Rabbit  
Result : Moderate eye irritation

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Moxifloxacin HCL:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: positive

Test Type: Chromosome aberration test in vitro  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Test Type: in vitro micronucleus test  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo  
cytogenetic assay)  
Application Route: Oral  
Result: negative



**Moxifloxacin Solid Formulation**

Version 2.4      Revision Date: 13.10.2021      SDS Number: 1731672-00008      Date of last issue: 23.03.2020  
Date of first issue: 05.06.2017

---

**Carcinogenicity**

Not classified based on available information.

**Reproductive toxicity**

Suspected of damaging the unborn child.

**Components:****Moxifloxacin HCL:**

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Oral  
Fertility: LOAEL: 500 mg/kg body weight  
Result: Effects on fertility

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Monkey  
Application Route: Oral  
Developmental Toxicity: NOAEL: 10 mg/kg body weight  
Result: negative

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Intravenous injection  
Developmental Toxicity: LOAEL: 20 mg/kg body weight  
Symptoms: Skeletal malformations

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

**STOT - single exposure**

Not classified based on available information.

**STOT - repeated exposure**

May cause damage to organs through prolonged or repeated exposure.

**Components:****Moxifloxacin HCL:**

Target Organs : Liver  
Assessment : May cause damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****Moxifloxacin HCL:**

Species : Rat  
LOAEL : 100 mg/kg  
Application Route : Oral  
Exposure time : 4 Weeks

Species : Rat  
NOAEL : 100 mg/kg

**Moxifloxacin Solid Formulation**

Version 2.4      Revision Date: 13.10.2021      SDS Number: 1731672-00008      Date of last issue: 23.03.2020  
Date of first issue: 05.06.2017

---

Application Route : Oral  
Exposure time : 13 Weeks  
Target Organs : Liver  
Symptoms : Liver disorders

Species : Rat  
NOAEL : 20 mg/kg  
Application Route : Oral  
Exposure time : 6 Months  
Target Organs : Liver  
Symptoms : Liver disorders

Species : Monkey  
NOAEL : 50 mg/kg  
Application Route : Oral  
Exposure time : 4 Weeks  
Symptoms : No adverse effects

Species : Monkey  
NOAEL : 15 mg/kg  
Application Route : Oral  
Exposure time : 13 Weeks  
Target Organs : Gastrointestinal tract  
Symptoms : Vomiting

Species : Monkey  
Application Route : Oral  
Exposure time : 26 Weeks  
Target Organs : Liver  
Symptoms : Liver disorders

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Moxifloxacin HCL:**

Ingestion : Symptoms: Nausea, Abdominal pain, Headache, Dizziness, central nervous system effects, joint pain

---

**SECTION 12: Ecological information****12.1 Toxicity**

No data available

**12.2 Persistence and degradability**

No data available

**12.3 Bioaccumulative potential**

No data available

**12.4 Mobility in soil**

No data available

## Moxifloxacin Solid Formulation

Version 2.4      Revision Date: 13.10.2021      SDS Number: 1731672-00008      Date of last issue: 23.03.2020  
Date of first issue: 05.06.2017

---

### 12.5 Results of PBT and vPvB assessment

**Product:**

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

### 12.6 Other adverse effects

**Product:**

Endocrine disrupting potential : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

---

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

## SECTION 14: Transport information

### 14.1 UN number

Not regulated as a dangerous good

### 14.2 UN proper shipping name

Not regulated as a dangerous good

### 14.3 Transport hazard class(es)

Not regulated as a dangerous good

### 14.4 Packing group

Not regulated as a dangerous good

### 14.5 Environmental hazards

Not regulated as a dangerous good

### 14.6 Special precautions for user

Not applicable

### 14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

## Moxifloxacin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.4	13.10.2021	1731672-00008	Date of first issue: 05.06.2017

---

### SECTION 15: Regulatory information

#### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

#### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

### SECTION 16: Other information

Other information	:	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
-------------------	---	--

#### Full text of H-Statements

H302	:	Harmful if swallowed.
H319	:	Causes serious eye irritation.
H361d	:	Suspected of damaging the unborn child.
H373	:	May cause damage to organs through prolonged or repeated exposure.

#### Full text of other abbreviations

Acute Tox.	:	Acute toxicity
Eye Irrit.	:	Eye irritation
Repr.	:	Reproductive toxicity
STOT RE	:	Specific target organ toxicity - repeated exposure
ZA OEL	:	South Africa. Hazardous Chemical Substances Regulations, Occupational Exposure Limits
ZA OEL / TWA OEL-RL	:	Long term occupational exposure limits - recommended limit
ZA OEL / STEL OEL-RL	:	Short term occupational exposure limits - recommended limit

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organiza-

**Moxifloxacin Solid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
2.4	13.10.2021	1731672-00008	Date of first issue: 05.06.2017

tion; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

**Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

**Classification of the mixture:**

Acute Tox. 4	H302
Eye Irrit. 2	H319
Repr. 2	H361d
STOT RE 2	H373

**Classification procedure:**

Calculation method
Calculation method
Calculation method
Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN